Acarix AB ("Acarix" or the "Company") has completed the new share issue of a maximum of
34,541,064 shares with preferential rights for the Company's existing shareholders, which was
resolved upon by the board of directors on the 25 September 2019, pursuant to the authorization
from the extra general meeting on 16 August 2019 (the "Rights Issue"). Acarix today announce
the final outcome of the Rights Issue.
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.